Hochmair, M. J., Fabikan, H., Illini, O., Weinlinger, C., Setinek, U., Krenbek, D., . . . Valipour, A. (2020). Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. Pharmaceuticals (Basel).
शिकागो स्टाइल उद्धरणHochmair, Maximilian J., et al. "Later-Line Treatment With Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis." Pharmaceuticals (Basel) 2020.
एमएलए उद्धरणHochmair, Maximilian J., et al. "Later-Line Treatment With Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis." Pharmaceuticals (Basel) 2020.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.